Table 1 The clinicopathologic characteristics of the patients performed uterus preserving cystectomy and uterus excision cystectomy
UPC (n = 63) | UEC (n = 49) | p | |
|---|---|---|---|
Age (yr) | 67.3 ± 12.2 | 67.7 ± 9.2 | 0.855a |
BMI (kg/m2) | 22.9 (21.1–26.3) | 23.9 (21.7–26.6) | 0.205b |
ASA score | 0.961b | ||
1 | 5 (7.9%) | 1 (2.0%) | |
2 | 46 (73.0%) | 41 (83.7%) | |
3 | 12 (19%) | 7 (14.3%) | |
ORC | 46 (73.0%) | 38 (77.6%) | 0.582c |
LRC | 17 (27.0%) | 11 (22.4%) | |
Type of urinary diversion | 0.100c | ||
Cutaneous ureterostomy | 29 (46.0%) | 18 (36.7%) | |
Ileal conduit | 30 (47.6%) | 31 (63.3%) | |
Orthotopic neobladder | 4 (6.3%) | 0 (0%) | |
Time of operation (mins) | 294.8 ± 104.3 | 296.1 ± 120.0 | 0.950a |
Bleeding volume during operation(L) | 500 (200–800) | 400 (200–650) | 0.321b |
Intraoperative transfusion(L) | 200 (0–650) | 200 (0–725) | 0.762b |
Clavien-Dindo class | 0.061b | ||
0 | 30 (47.6%) | 32 (65.3%) | |
1 | 2 (3.2%) | 2 (4.1%) | |
2 | 30 (47.6%) | 14 (28.6%) | |
3 | 0 (0%) | 0 (0%) | |
4 | 1 (1.6%) | 0 (0%) | |
5 | 0 (0%) | 1 (2%) | |
Postoperative stay (days) | 11 (8–17) | 9 (8–12) | 0.076b |
Postoperative fasting time (days) | 5 (3–5) | 5 (3–6) | 0.537b |
Location of the tumor | 0.399c | ||
Posterior wall or trigone | 43 (68.3%) | 37 (75.5%) | |
Other location | 20 (31.7%) | 12 (24.5%) | |
Preoperative clinical stage | 0.017c | ||
Ta and Tis and T1 | 18 (28.6%) | 12 (24.5%) | |
T2 | 26 (41.3%) | 16 (32.7%) | |
T3 | 19 (30.2%) | 14 (28.6%) | |
T4 | 0 (0%) | 7 (14.3%) | |
Pathologic stage | 0.613c | ||
Ta and Tis and T1 | 18 (28.6%) | 10 (20.4%) | |
T2 | 22 (34.9%) | 19 (38.8%) | |
T3 and T4 | 23 (36.5%) | 20 (40.8%) | |
Pathologic nodal stage | 0.002c | ||
N0 | 60 (95.2%) | 37 (75.5%) | |
N+ | 3 (4.8%) | 12 (24.5%) | |
Pathologic grade | 1.000c | ||
Low grade | 7 (11.1%) | 5 (10.2%) | |
High grade | 55 (87.3%) | 44 (89.8%) | |
Negative margin | 60 (95.2%) | 47 (95.9%) | 1.000c |
Positive margin | 3 (4.8%) | 2 (4.1%) | |
No neoadjuvant/adjuvant chemotherapy | 55 (88.7%) | 39 (81.3%) | 0.271c |
Neoadjuvant/adjuvant chemotherapy | 7 (11.3%) | 9 (18.8%) |